Journal
MOVEMENT DISORDERS
Volume 25, Issue 2, Pages 224-228Publisher
WILEY
DOI: 10.1002/mds.22907
Keywords
Huntington's disease; uric acid; progression
Categories
Funding
- NIH, NINDS [NS R01-35284]
- General Clinical Research Centers [RR00052, RR00645, RR00042, RR00044, RR01066, RR07122]
- AstraZeneca
- Vitaline
- National Institutes of Health (NEI, NINDS, NIA)
- Michael J. Fox Foundation
- Medivation
- Neurosearch
- Pfizer
- National Institutes of Health
- Food and Drug Administration
- Spinal Muscular Atrophy Foundation
- Muscular Dystrophy Association
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Neurosearch Sweden AB
- Employment University of Rochester
Ask authors/readers for more resources
Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE-HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. (C) 2010 Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available